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Askgaard et al., 2015Deaths from liver disease have increased dramatically over the past
30 years and one of the culprits for this increase is excessive alcohol
consumption. Using the Danish Cancer, Diet, and Health study, which
included 55,917 participants over an 8-year period, Askgaard and col-
leagues showed that daily drinking was worse than drinking 3–4
days per week and the risk of liver cirrhosis started at 14 units
consumption per week. This is important given that the current
recommendation regarding safe limits of alcohol is 21 units per week.
Clearly, current recommendations will need to be revisited. Also the
study provided novel data showing that compared to beer and liquor,
wine might be associated with a lower risk of alcoholic cirrhosis.LIVER CANCERCCRK
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Feng et al., 2015Gender and histone
modiﬁcations, HCC in
patients who achieved
serum HBsAg
clearance, radiological
assessment after TACE,
sorafenib therapy, liver
resection
HCC is most common in males
than females and the reasons for
this difference are poorly known.
Lysine methyl transferases
(KMTs) catalyze the transfer of
one, two, or three methyl groups
from S-adenosyl-L-methionine to
the e-amino group of a lysine
residue on a histone to generate
mono-, di-, and trimethylated
histones. The KMT6 family
methylates histone H3K27 and
exists within a complex. The
methylase activity of KMT6 is
due to enhancer of zeste 2
polycomb repressive complex 2
subunit (EZH2); the other
components of the complex are
SUZ12, EED, and RBBP4/7.Deregulation of certain members
of the KMT6 complex has
been shown in cancer. Cell
cycle-related kinase (CCRK,
encoded by CDK20) is involved
in liver carcinogenesis. Feng et
al., using sophisticated
approaches, investigated the
potential cross-talk between the
EZH2 and CCRK in the context
of liver cancer. They showed
that CCRK expression in
immortalized human liver cells
resulted in increased EZH2 and
H3K27 trimethylation and
stimulated proliferation and
tumor formation. CCRK by
inhibiting glycogen synthase
kinase 3b stimulated a b-catenin/
TCF/E2F1/EZH2 module that
epigenetically enhanced
androgen receptor (AR)
signaling. Simultaneously,
CCRK facilitated the
co-occupancy of CCRK promo-
ter by EZH2-AR and its subse-
quent transcriptional activation.
These ﬁndings reveal an
epigenetic vicious cycle in
liver carcinogenesis thatJournal of Hepatologyinvolves reciprocal regulation
of CCRK and EZH2 suggesting
targets for new therapies.
Whether patients with chronic
hepatitis B who have achieved
serum HBsAg clearance should
be screened for hepatocellular
carcinoma (HCC) development
is unknown. Kim et al. addressed
this question in a retrospective
analysis of a cohort of 829
Korean patients. They showed
that the presence of HCC2015 vol. 62 j 991–994should be screened in
patients with cirrhosis, and in
patients who do not have cir-
rhosis if these are males, older
than 50 years and infected
with HBV genotype C. Clear-
ance HBsAg from serum in indi-
viduals of 50 years or more is an
independent predictor for HCC.
Kim et al. retrospectively
investigated which is the best
radiological method for
measuring HCC treated by
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JOURNAL OF HEPATOLOGYtrans-arterial chemoembolization
(TACE) in order to assess
suitability for liver transplanta-
tion. A total of 271 patients with
HCC treated with TACE prior to
liver transplantation were
classiﬁed according to both the
Milan and up-to-seven criteria
after TACE using the enhance-
ment or size method on
computed tomography images.
The authors found that
enhancement method is
appropriate for assessing the
control or down-staging of
HCC within Milan after TACE.
However, the size method
seems to be better when
applying the up-to-seven
criterion.
Sorafenib therapy is used for
HCC with extrahepatic spread.
However, sorafenib therapy is
frequently discontinued due to
adverse events such as
deterioration of liver function
and/or performance. Sohn et al.
investigated retrospectively the
outcome and prognostic factors
of sorafenib treatment in 254
patients with HCC and extrahe-
patic spread in whom sorafenib
was administered for at least
8 weeks. Sorafenib prolonged
survival in patients with
extrahepatic spread who
achieved disease control
(deﬁned when the tumor992response was satisfactory,
i.e., complete or partial
remission, or evidence of
stable disease according to
the RECIST criteria). Intrahe-
patic tumor is a poor prognostic
factor for both disease progres-
sion and overall survival in HCC
patients with extrahepatic spread
treated with sorafenib.
Repeated hepatectomy is
used to treat recurrent HCC or
liver metastasis from colorectal
cancer. However, repeated
hepatectomy may result in
postoperative adhesion and
decrease in liver regenerative
capacity. Inagaki et al. asked
whether a fetal liver mesothelial
cells (FL-MCs) sheet could solve
these two clinical issues
simultaneously. They showed
that the FL-MCs sheet was able
to both prevent postoperative
adhesion and promote liver
regeneration in both syngeneic
and allogeneic transplantation,
and hence FL-MCs may serve
as a potentially useful cell
source for regenerative
medicine after hepatectomy.
Treatment decisions for HCC
are guided by tumor size. Kluger
et al. aimed to analyze resection
outcomes according to tumor
size and characterize prognostic
factors. By studying a large
group of 303 patients across aJournal of Hepatology 2distribution of tumor sizes and
background liver diseases, they
found that size alone provided
limited prognostic information.
Tumor biology and underlying
liver function were better
predictors of prognosis and
should be taken into account.NON-ALCOHOLIC
FATTY LIVER DISEASE
(NAFLD)
Anthocyanins, TRAIL
receptor, disease
progression, TSH and
bile acids, early
menarche and disease
risk
Anthocyanins are water-soluble
ﬂavonoids that have beneﬁcial
effects due to its antioxidant
properties. In this issue,
Morrison et al. demonstrate that
mirtoselect, an anthocyanin-rich
bilberry extract, attenuates the
degree of steatosis and
inﬂammation in experimental
NASH. Further studies should
investigate the safety and
efﬁcacy of this promising type of
compounds in humans.
Targeting inﬂammatory
mediators could be beneﬁcial in
patients with metabolic
syndrome. Idrissova et al.
provide convincing evidence that
TRAIL receptor (encoded by
TNFSF10, a gene of the TNF
receptor superfamily) signaling
plays an important role in the
pathogenesis of obesity-
associated inﬂammation.
Genetic deletion of trail receptor
completely repressed weight
gain, adiposity and insulin
resistance and attenuated the
development of NASH in high
fat-fed mice. These data
advance the concept that
macrophage-associated hepatic
and adipose tissue inﬂammation
of nutrient excess requires trail
receptor signaling.
The factors that predict
progression of NAFLD are not
well known. In this issue,
McPherson et al. performed a
relevant study using paired
biopsies in patients with NAFLD.015 vol. 62 j 991–994Almost half of the patients have
ﬁbrosis progression, some of
them to advanced forms.
Interestingly, some patients with
simple steatosis at baseline
developed ﬁbrosis, suggesting
that the current dogma that
simple steatosis is a benign
condition should be revisited.
Elevated TSH levels are
frequently found in patients with
NAFLD. Bile acids play a crucial
role in dietary fat digestion and in
the regulation of lipid, glucose,
and energy metabolism. Song
et al. investigated the impact of
TSH on bile acid homeostasis.
They demonstrated that TSH
represses hepatic bile acid
synthesis via SREBP-2/HNF-4a/
CYP7A1 axis, which strongly
supports that TSH is an
important regulator of bile acid
homeostasis in liver indepen-
dently of thyroid hormones.
The percentage of girls with
early menarche has increased in
the last two decades worldwide.
Girls who experienced early
menarche are signiﬁcantly more
often overweight/obese.
However, whether early
menarche predisposes to
NAFLD was unknown. In this
issue of the Journal, Ryu et al.
identiﬁed an inverse association
between age at menarche and
NAFLD in a large sample of
middle-aged Korean women.
This association was partially
mediated by adiposity. The
ﬁndings of this study suggest
that obesity prevention
strategies are needed in women
who undergo early menarche to
reduce the risk of NAFLD.HEPATITIS C
SART-1 regulates
antiviral effector genes,
new treatment
approaches for HCV
type 4, simeprevir-
associated resistance
How interferons (IFN) exert their
antiviral state in HCV infection
still remains unclear. However,
there is growing evidence that
many host factors, independent
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of the classical JAK-STAK
pathway, are involved. Now Lin
et al. showed that SART-1
(squamous cell carcinoma
antigen recognized by T cells), a
component of the spliceosome
involved in mRNA processing
and splicing regulates HCV
replication through differential
expression and alternative
splicing of mRNAs expressed
by antiviral effector genes
including MX1 and OAS3. The
observation that HCV infection
reduces SART1 expression may
be taken as a strong argument
that HCV promotes its persis-
tence through suppression of
multiple levels of host innate
immunity, hereby including not
only the classical IFN-JAK-STAT
pathway but also host
components of the spliceosome.
HCV type 4 accounts for
approximately 13% of the world’s
HCV-infected population and is
the most prevalent HCV type in
North Africa/Middle East and
Central Sub-Saharan Africa.
However, limited data are
available at present to guide
clinical decision-making in
patients with chronic HCV type 4
infection. In this issue of the
Journal three studies focus
exclusively on the treatment of
HCV type 4 and were further
highlighted by an Editorial.
In a response guided concept
study Moreno et al. evaluated in
an open-label, single-arm study
(RESTORE) the efﬁcacy and
safety of a 12 week simeprevir
with PegIFN/ribavirin triple
regimen followed by
12–36 weeks of PegIFN/RBV
maintenance in naı¨ve or experi-
enced patients chronically
infected with HCV genotype 4.
Sustained response rates were
especially high in treatment-
naı¨ve and prior relapser patients
fulﬁlling response-guided criteria
for 24 weeks (93.5% and 95.0%,
respectively), but limited efﬁcacy
was shown for prior partial and
null responders (60% and 40%,
respectively).
The study by Ruane et al. in
which 60 patients of Egyptian
ancestry were randomly allo-cated in a 1:1 ratio to receive an
IFN-free regimen of sofosbuvir
and ribavirin for 12 or 24 weeks
clearly demonstrates the
advantage of extending
treatment duration to
24 weeks hereby increasing
SVR rates from 68% (12 weeks)
to 93%.
A 12 week regimen of three
direct acting antivirals – the
NS5A inhibitor daclatasvir, the
NS3 protease inhibitor
asunaprevir plus the non-
nucleoside NS5B polymerase
inhibitor beclabuvir (either 75 mg
or 150 mg) – resulted in a 100%
SVR rate as shown by
Hassanein et al. in their
exploratory study in 21
non-cirrhotic HCV type
4-infected patients from the
United States.
Simeprevir plus PegIFNa/
ribavirin treatment of HCV
genotype 1a patients with a NS3
protease Q80K polymorphism at
baseline is not recommended
according to clinical guidelines.
Lenz et al. analyzed this problem
in more depth by describing
mechanisms that may lead to
lower SVR rates in this patient
population. Undertaken were
also comprehensive
characterizations of emerging
resistant mutations in patients
not achieving SVR in clinical
phase II and III studies. Given
the wide use of simeprevir in
combination with other drugs
these ﬁndings are highly
relevant.HEPATITIS B
Predicting HBsAg loss
by hepatitis B viral
diversity, immune
evasion by disrupting
MVP-MyD88 interaction
To date, little is known about the
predictive nature of any viral
factors for loss of HBsAg under
nucleos(t)ide analog therapy. In
an elegant study, Charuworn
et al. showed for the ﬁrst time
that certain patterns in inter-
patient viral diversity across
the entire HBV type A and DJournal of Hepatology 20coding region observed at the
time of treatment initiation were
associated with HBsAg loss
on TDF therapy. These results
suggest that it should be
possible to construct a model
that can predict prior to the start
of antiviral therapy which
patients might achieve HBsAg
loss, which would be a signiﬁcant
step forward in the care of
chronically HBV-infected
patients.
The mechanisms that are
involved in establishing and
maintaining chronic HBV
infections are still not well
understood. Major vault protein
(MVP) is a novel virus-induced
host factor which upregulates
type-I IFN production, leading to
cellular antiviral response. Liu
et al. are providing a new model
of innate immune escape in
chronic HBV infection by
demonstrating that HBsAg as
well as HBeAg speciﬁcally
bind virus-induced MVP,
which in turn led to blocking of
the molecular interaction
between MVP and MyD88 (an
adaptor that transduces
toll-like receptor signaling), and
suppression of the MVP-
induced NF-jB and IFN
signaling.15 vol. 62 j 991–994CIRRHOSIS AND
PORTAL
HYPERTENSION
Proton pump inhibitors
and SBP, non-invasive
diagnosis of clinically
signiﬁcant portal
hypertension
The debate about whether
consumption of proton pump
inhibitors increase the risk of
spontaneous bacterial peritonitis
in cirrhotic patients has been
ongoing for a considerable
length of time fuelled by data
from small retrospective studies.
The study by Terg et al. from
Argentina, prospectively
included 700 patients in 23 cen-
ters and showed conclusively
that intake of proton pump
inhibitors is NOT associated
with SBP. These data provide a
convincing and clear answer to a
longstanding ongoing debate.
One of the major limitations
to adequate management of
portal hypertension and drug
development in this area is the
need for invasive measurements
of portal pressure. The paper by
Procopet et al. provides new and
exciting data showing
convincingly that an ultrasound
machine based technology, real993
Richard Moreau⁄ at Inserm U1149, Centre de Recherche sur l’Inﬂamm
Diderot, Paris, France; DHU UNITY, Service d’He´patologie, Hoˆpital Bea
Inﬂamex, CoMUE Sorbonne Paris Cite´, Paris, France.
*Corresponding author. E-mail address: richard.moreau@inserm.fr.
Ramon Bataller at Division of Gastroenterology and Hepatology, Departm
Hill, Chapel Hill, North Carolina, USA.
Thomas Berg at Clinic for Gastroenterology, Section Hepatology, Unive
Jessica Zucman-Rossi at Inserm UMR-674; Ge´nomique Fonctionnelle
Labex Immuno-oncology; Faculte´ de Me´decine; Sorbonne Paris Cite´; Pa
Rajiv Jalan at Liver Failure Group, Institute for Liver and Digestive Hea
Liver Stiffness (RT−SWE) and CSPH
Average false positive rate
Av
er
ag
e 
tru
e 
po
si
tiv
e 
ra
te
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
6.70
14.16
21.61
29.07
36.53
43.99
Procopet et al., 2015
JOURNAL OF HEPATOLOGY
994 Journal of Hepatology 2time shear wave elastography,
provides reliable data to diag-
nose clinically signiﬁcant
portal hypertension in the vast
majority of patients with a high
degree of certainty.LIVER INJURY
Paracetamol can
produce liver toxicity in
pregnant mothers and
fetuses
Recent studies have shown that
administration of paracetamol
(acetaminophen) during preg-
nancy can increase the risk of
asthma in children. It has alsoation (CRI), Clichy and Paris, Fran
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015 vol. 62 j 991–994been argued for some time that
paracetamol may not be com-
pletely safe from liver toxicity
even when administered in
recommended doses. The study
by Karimi et al. explores the
question whether paracetamol
can produce liver injury in the
pregnant mother and the new-
born fetus in an animal model.
They show that paracetamol
administration can result in
liver toxicity in the pregnant
mother and reduces stem
cells in the fetus as well as
inducing inﬂammation of the
airways. Their results could
change clinical practice if
conﬁrmed.ce; UMRS1149, Universite´ Paris
de Paris, Clichy, France; Labex
ersity of North Carolina at Chapel
any.
nce; Universite´ Paris Descartes;
Free Hospital, UK.
